Salvage immunotherapy of malignant glioma

M. Ingram, S. Jacques, D. B. Freshwater, G. B. Techy, C. H. Shelden and J. T. Helsper
Experimental and Clinical Immunotherapy Laboratory, Huntington Medical Research Institutes, Pasadena, CA 91101.

We present the preliminary results of a phase I trial of adoptive immunotherapy for recurrent or residual malignant glioma. The protocol is based on surgical debulking followed by implantation into the tumor bed of autologous lymphocytes that have been stimulated with phytohemagglutinin-P and then cultured in vitro in the presence of interleukin 2. Fifty-five patients with a mean Karnofsky rating of 64 were treated between February 1985 and March 1987. No significant toxicity was associated with the immunotherapy. Fifty patients had a positive initial response to therapy, nine patients had early recurrence (two to four months after treatment), and 22 patients died. We comment on major differences between the protocol described and other immunotherapy protocols.